(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 March 2006 (30.03.2006)

PCT

(10) International Publication Number
WO 2006/034488 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2005/034353

(22) International Filing Date:
22 September 2005 (22.09.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/612,468 23 September 2004 (23.09.2004) US
60/696,353 30 June 2005 (30.06.2005) US

(71) Applicant *(for all designated States except US)*: **GENENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080-4990 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **EIGENBROT, Charles W.** [US/US]; 1129 Bernal Avenue, Burlingame, California 94010 (US). **JUNUTULA, Jagath Reddy** [IN/US]; 34391 Tupelo Street, Fremont, California 94555 (US). **LOWMAN, Henry** [US/US]; P. O. Box 2556, 400 San Juan Avenue, El Granada, California 94018 (US). **RAAB, Helga E.** [DE/US]; 715 Shields Street, San Francisco, California 94132 (US). **VANDLEN, Richard** [US/US]; 1015 Hayne Road, Hillsborough, California 94010 (US).


(74) Agent: **ANDRUS, Alex**; Genentech, Inc., MS 49, 1 DNA Way, South San Francisco, California 94080 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]

(54) Title: CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES



(57) Abstract: Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab), optionally with an albumin-binding peptide (ABP) sequence, are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered antibody-drug conjugates having Formula I: Ab-(L-D)$_p$ I where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.

WO 2006/034488 A2

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.